GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

In this week’s edition of InnovationRx, we look at RFK Jr.’s vaccine advisory committee purge, a tech billionaire’s funding ...

Meissner was previously listed in April as a consultant to the RSV vaccines work group for the CDC committee, before Kennedy ...

Robert F. Kennedy Jr. faced questions from Congress about his own potential conflicts of interest during a confirmation ...

Staff who provide data to the vaccine panel have been pushed aside, according to health officials, raising doubts about the ...